{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T20:36:35Z","timestamp":1760646995478},"reference-count":17,"publisher":"Japan Endocrine Society","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Endocr J"],"published-print":{"date-parts":[[2019]]},"DOI":"10.1507\/endocrj.ej18-0553","type":"journal-article","created":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T18:02:29Z","timestamp":1554141749000},"page":"571-574","source":"Crossref","is-referenced-by-count":10,"title":["Drug-induced hyperglycemia in the Japanese Adverse Drug Event Report database: association of evelolimus use with diabetes"],"prefix":"10.1507","volume":"66","author":[{"given":"Hiromi","family":"Konishi","sequence":"first","affiliation":[{"name":"Department of Endocrinology and Metabolism, Yokohama City University Graduate School of Medicine, Yokohama, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Shirakawa","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Yokohama City University Graduate School of Medicine, Yokohama, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masanori","family":"Arai","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Yokohama City University Graduate School of Medicine, Yokohama, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuo","family":"Terauchi","sequence":"additional","affiliation":[{"name":"Department of Endocrinology and Metabolism, Yokohama City University Graduate School of Medicine, Yokohama, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"386","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Baselga J, Campone M, Piccart M, Burris HA 3rd, Rugo HS, et al. (2012) Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 366: 520\u2013529.","DOI":"10.1056\/NEJMoa1109653"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Franz DN, Belousova E, Sparagana S, Bebin EM, Frost M, et al. (2013) Efficacy and safety of everolimus for subependymal giant cell astrocytomas associated with tuberous sclerosis complex (EXIST-1): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 381: 125\u2013132.","DOI":"10.1016\/S0140-6736(12)61134-9"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Hess G, Herbrecht R, Romaguera J, Verhoef G, Crump M, et al. (2009) Phase III study to evaluate temsirolimus compared with investigator\u2019s choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol 27: 3822\u20133829.","DOI":"10.1200\/JCO.2008.20.7977"},{"key":"4","doi-asserted-by":"publisher","unstructured":"4 Motzer RJ, Escudier B, Oudard S, Hutson TE, Porta C, et al. (2008) Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 372: 449\u2013456.","DOI":"10.1016\/S0140-6736(08)61039-9"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, et al. (2011) Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 364: 514\u2013523.","DOI":"10.1056\/NEJMoa1009290"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Chresta CM, Davies BR, Hickson I, Harding T, Cosulich S, et al. (2010) AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with <i>in vitro<\/i> and <i>in vivo<\/i> antitumor activity. Cancer Res 70: 288\u2013298.","DOI":"10.1158\/0008-5472.CAN-09-1751"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Kleinert M, Sylow L, Fazakerley DJ, Krycer JR, Thomas KC, et al. (2014) Acute mTOR inhibition induces insulin resistance and alters substrate utilization <i>in vivo<\/i>. Mol Metab 3: 630\u2013641.","DOI":"10.1016\/j.molmet.2014.06.004"},{"key":"8","doi-asserted-by":"publisher","unstructured":"8 Fraenkel M, Ketzinel-Gilad M, Ariav Y, Pappo O, Karaca M, et al. (2008) mTOR inhibition by rapamycin prevents beta-cell adaptation to hyperglycemia and exacerbates the metabolic state in type 2 diabetes. Diabetes 57: 945\u2013957.","DOI":"10.2337\/db07-0922"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Morviducci L, Rota F, Rizza L, Di Giacinto P, Ramponi S, et al. (2018) Everolimus is a new anti-cancer molecule: metabolic side effects as lipid disorders and hyperglycemia. Diabetes Res Clin Pract 143: 428\u2013431.","DOI":"10.1016\/j.diabres.2018.04.001"},{"key":"10","unstructured":"10 Verges B (2018) mTOR and cardiovascular diseases: diabetes mellitus. Transplantation 102: S47\u2013S49."},{"key":"11","unstructured":"11 Arai M, Shirakawa J, Konishi H, Sagawa N, Terauchi Y (2018) Bullous pemphigoid and dipeptidyl peptidase 4 inhibitors: a disproportionality analysis based on the Japanese Adverse Drug Event Report database. Diabetes Care 41: e130\u2013e132."},{"key":"12","doi-asserted-by":"publisher","unstructured":"12 Pavel ME, Hainsworth JD, Baudin E, Peeters M, Horsch D, et al. (2011) Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet 378: 2005\u20132012.","DOI":"10.1016\/S0140-6736(11)61742-X"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Hurvitz SA, Andre F, Jiang Z, Shao Z, Mano MS, et al. (2015) Combination of everolimus with trastuzumab plus paclitaxel as first-line treatment for patients with HER2-positive advanced breast cancer (BOLERO-1): a phase 3, randomised, double-blind, multicentre trial. Lancet Oncol 16: 816\u2013829.","DOI":"10.1016\/S1470-2045(15)00051-0"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, et al. (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356: 2271\u20132281.","DOI":"10.1056\/NEJMoa066838"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Rini BI, Bellmunt J, Clancy J, Wang K, Niethammer AG, et al. (2014) Randomized phase III trial of temsirolimus and bevacizumab <i>versus<\/i> interferon alfa and bevacizumab in metastatic renal cell carcinoma: INTORACT trial. J Clin Oncol 32: 752\u2013759.","DOI":"10.1200\/JCO.2013.50.5305"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Wolff AC, Lazar AA, Bondarenko I, Garin AM, Brincat S, et al. (2013) Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer. J Clin Oncol 31: 195\u2013202.","DOI":"10.1200\/JCO.2011.38.3331"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Rothman KJ, Lanes S, Sacks ST (2004) The reporting odds ratio and its advantages over the proportional reporting ratio. Pharmacoepidemiol Drug Saf 13: 519\u2013523.","DOI":"10.1002\/pds.1001"}],"container-title":["Endocrine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/66\/6\/66_EJ18-0553\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,28]],"date-time":"2019-06-28T23:36:58Z","timestamp":1561765018000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/endocrj\/66\/6\/66_EJ18-0553\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"references-count":17,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1507\/endocrj.ej18-0553","relation":{},"ISSN":["0918-8959","1348-4540"],"issn-type":[{"value":"0918-8959","type":"print"},{"value":"1348-4540","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019]]}}}